


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A quinazoline derivative of the Formula (I):



wherein:

either R<sup>2</sup> is in the 6-position and the substituted-pyrrolidinyl group is in the 7-position of the quinazoline ring or R<sup>2</sup> is in the 7-position and the substituted-pyrrolidinyl group is in the 6-position of the quinazoline ring;

A is phenyl or pyridyl;

each R<sup>1</sup> is a substituent on a ring carbon atom in ring A and is independently selected from halogeno, cyano, nitro, hydroxy, carboxy, trifluoromethyl, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkoxycarbonyl, ureido, N-(1-6C)alkylureido, N,N-di-[(1-6C)alkyl]ureido, -NR<sup>a</sup>R<sup>b</sup>, -SO<sub>2</sub>NR<sup>a</sup>R<sup>b</sup> and a group of the formula -CONR<sup>a</sup>R<sup>b</sup> [wherein R<sup>a</sup> is hydrogen or (1-6C)alkyl and R<sup>b</sup> selected from hydrogen, (1-6C)alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl(1-3C)alkyl, heteroaryl,

heteroaryl(1-3C)alkyl, (3-7)cycloalkyl and (3-7)cycloalkyl(1-3C)alkyl wherein any alkyl, heterocyclyl, heteroaryl and cycloalkyl groups in R<sup>a</sup> and R<sup>b</sup> are optionally substituted by 1, 2 or 3 substituents selected from (1-4C)alkyl, halogeno, hydroxy and (1-4C)alkoxy;

or R<sup>a</sup> and R<sup>b</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6-membered ring which optionally contains an additional ring heteroatom selected from nitrogen, oxygen and sulphur and which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl [provided the ring is not thereby quaternised].

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by R<sup>a</sup> and R<sup>b</sup> together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxyl, (1-4C)alkyl and (1-4C)alkoxy;

or, when two R<sup>1</sup> groups are attached to adjacent carbon atoms, they may, together with the carbon atoms to which they are attached, form a pyrrole ring, wherein the pyrrole ring is optionally substituted by 1 or 2 substituents independently selected from (1-6C)alkyl, halogeno, cyano, nitro, hydroxy, amino, carbamoyl, sulfamoyl and trifluoromethyl; or, when two R<sup>1</sup> groups are attached to adjacent carbon atoms, they may, together form a (1-3C)alkylenedioxy group [-O(CH<sub>2</sub>)<sub>1-3</sub>O];

m is 0, 1, 2 or 3;

each R<sup>2</sup> is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-3C)alkyl and a group of the formula R<sup>7</sup>O-, wherein R<sup>7</sup> is (1-6C)alkyl

optionally substituted by 1, 2 or 3 substituents independently selected from hydroxy and a group of the formula  $R^8O-$  [ ] wherein  $R^8$  is (1-3C)alkyl[ ];

$R^3$  is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-3C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (2-6C)alkanoyl, carbamoyl(1-6C)alkyl, N-(1-6C)alkylcarbamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl(1-6C)alkyl, sulfamoyl(1-6C)alkyl, N-(1-6C)alkylsulfamoyl(1-6C)alkyl, N,N-di-[(1-6C)alkyl]sulfamoyl(1-6C)alkyl and (2-6C)alkanoyl(1-6C)alkyl,

and wherein any (1-6C)alkyl or (2-6C)alkanoyl group within  $R^3$  is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, nitro, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy and  $NR^cR^d$ , wherein  $R^c$  is hydrogen or (1-4C)alkyl and  $R^d$  is hydrogen or (1-4C)alkyl and wherein any (1-4C)alkyl in  $R^c$  or  $R^d$  is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from cyano, nitro and (1-4C)alkoxy,

or  $R^c$  and  $R^d$  together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which optionally contains an additional ring heteroatom selected from nitrogen, oxygen and sulphur and which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl [ ] provided the ring is not thereby quaternised[ ],

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by  $R^c$  and  $R^d$  together with the nitrogen atom to which they are attached

is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy; each R<sup>4</sup> is independently selected from (1-4C)alkyl, (1-4C)alkoxy, cyano, halogeno, hydroxyl and oxo;

n is 0, 1 or 2;

R<sup>5</sup> is hydrogen or (1-6C)alkyl;

R<sup>6</sup> is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-3C)alkyl, (3-7)heterocyclyl(1-3C)alkyl and heteroaryl(1-3C)alkyl,

and wherein any (1-3C)alkyl, (1-6C)alkyl, (3-7)cycloalkyl, heteroaryl or heterocyclyl group within R<sup>5</sup> or R<sup>6</sup> is optionally substituted [[[ ]]] on any available carbon atoms[[[ ]]] by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen [[[ ]]] provided the ring is not thereby quaternised[[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl [[[ ]]] provided the ring is not thereby quaternised[[[ ]]]],

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

provided that when the pyrrolidinyl group is linked to the 6-position of the quinazoline ring, m is 2 and substituents R<sup>1</sup> are both halogeno and attached to the 2- and 3-positions of the ring A, then R<sup>6</sup> is selected from ~~substituted (1-6C)alkyl (wherein~~ substituted (1-6C)alkyl is (1-6C)alkyl substituted by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy), (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, (3-7)heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-6C)alkyl, (3-7)heterocyclyl(1-6C)alkyl and heteroaryl(1-6C)alkyl,

and wherein any (3-7)cycloalkyl, heteroaryl or (3-7)heterocyclyl group within R<sup>6</sup> is optionally substituted ~~[[[]]]~~ on any available carbon atoms ~~[[[]]]~~ by 1, 2 or 3 substituents independently selected from halogeno, hydroxy, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heteroaryl or heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen ~~[[[]]]~~ provided the ring is not thereby quaternised ~~[[[]]]~~ by (1-4C)alkyl or (2-4C)alkanoyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or

two nitrogen atoms as the only hetero atoms present in the ring and which is optionally substituted on an available ring carbon atom by 1 or 2 substituents independently selected from hydroxy, carbamoyl, (1-4C)alkyl, and (1-3C)alkylenedioxy;

and wherein any 4, 5 or 6 membered heterocyclic ring formed by R<sup>5</sup> and R<sup>6</sup> is optionally substituted on any available ring nitrogen [[[ ]]] provided the ring is not thereby quaternised[[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl;

or a pharmaceutically-acceptable salt thereof.

2. (Currently Amended) A quinazoline derivative according to claim 1, wherein R<sup>5</sup> is hydrogen or (1-6C)alkyl and R<sup>6</sup> is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-3C)alkyl, (3-7)heterocyclyl(1-3C)alkyl and heteroaryl(1-3C)alkyl,

and wherein any (1-3C)alkyl, (1-6C)alkyl, (3-7)cycloalkyl, heteroaryl or heterocyclyl group within R<sup>5</sup> or R<sup>6</sup> is optionally substituted [[[ ]]] on any available carbon atoms[[[ ]]] by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen [[[ ]]] provided the ring is not thereby quaternised[[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any

available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl  
[[~~( )~~]] provided the ring is not thereby quaternised[[~~( )~~]],

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on  
the ring formed by R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached  
is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno  
and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

provided that when the pyrrolidinyl group is linked to the 6-position of the  
quinazoline ring, m is 2 and substituents R<sup>1</sup> are both halogeno and attached to the 2-  
and 3-positions of the ring A, then R<sup>6</sup> is selected from ~~substituted (1-6C)alkyl (wherein~~  
~~substituted (1-6C)alkyl is~~ (1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-7)heterocyclyl (wherein  
the heterocyclyl is carbon linked), heteroaryl, (3-7)heterocyclyl(1-6C)alkyl ~~[[~~( )~~]] wherein~~  
the heterocyclyl is carbon linked to the (1-6C)alkyl moiety[[~~( )~~]], and heteroaryl(1-6C)alkyl,  
(1-6C)alkyl substituted by 1, 2 or 3 substituents independently selected from (1-  
6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, ~~and oxo or~~ and a (1-  
6C)alkoxycarbonyl together with a hydroxy group), ~~(1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-~~  
~~7)heterocyclyl (wherein the heterocyclyl is carbon linked), heteroaryl, (3-~~  
~~7)heterocyclyl(1-6C)alkyl~~ ~~[[~~( )~~]] wherein the heterocyclyl is carbon linked to the (1-6C)alkyl~~  
~~moiety[[~~( )~~]]~~, and heteroaryl(1-6C)alkyl,

and wherein any heteroaryl or (3-7)heterocyclyl group within R<sup>6</sup> is optionally  
substituted ~~[[~~( )~~]]~~ on any available carbon atoms[[~~( )~~]] by 1, 2 or 3 substituents independently  
selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl,  
carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected  
from oxo, cyano, nitro and (1-4C)alkoxy, and wherein any heteroaryl or heterocyclyl

group within R<sup>sup.6</sup> is optionally substituted on any available ring nitrogen [[[ ]]] provided the ring is not thereby quaternised[[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl, or

R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or two nitrogen atoms as the only hetero atoms present in the ring and which is substituted on an available ring carbon atom by 1 or 2 substituents independently selected from carbamoyl and (1-3C)alkylenedioxy.

3. (Currently Amended) A quinazoline derivative according to claim 1-~~or claim 2~~, wherein R<sup>5</sup> is hydrogen, methyl, ethyl propyl, isopropyl or isobutyl and R<sup>6</sup> is selected from hydrogen, methyl, ethyl propyl, isopropyl, isobutyl, vinyl, isopropenyl, allyl, but-2-enyl ethynyl, 2-propynyl, butynyl, methoxy, ethoxy propoxy, isopropoxy, cyclopropyl, cyclopentyl, cyclohexyl, azetidiny, oxazepanyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, tetrahydropyrimidinyl, tetrahydrothienyl, tetrahydrothiopyranyl, thiomorpholinyl, pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, azetidylmethyl, oxazepanylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, tetrahydro-1,4-thiazinylmethyl, piperidinylmethyl, homopiperidinylmethyl, piperazinylmethyl, homopiperazinylmethyl, dihydropyridinylmethyl, tetrahydropyridinylmethyl, dihydropyrimidinylmethyl, tetrahydropyrimidinylmethyl, tetrahydrothienylmethyl, tetrahydrothiopyranyl, methyl,



thiomorpholinylmethyl, pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, thiadiazolylmethyl, 2-(azetidinyl)ethyl, 2-(oxazepanyl)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(tetrahydro-1,4-thiazinyl)ethyl, 2-(piperidinyl)ethyl, 2-(homopiperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(homopiperazinyl)ethyl, 2-(dihydropyridinyl)ethyl, 2-(tetrahydropyridinyl)ethyl, 2-(dihydropyrimidinyl)ethyl, 2-(tetrahydropyrimidinyl)ethyl, 2-(tetrahydrothienyl)ethyl, 2-(tetrahydrothiopyranyl)ethyl, 2-(thiomorpholinyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl, 2-(isothiazolyl)ethyl and 2-(thiadiazolyl)ethyl,

and wherein any alkyl, cycloalkyl, heteroaryl or heterocyclyl group within R<sup>5</sup> or R<sup>6</sup> is optionally substituted [[[[]]] on any available carbon atoms [[]]] by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido, propionamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy and ethoxy, and wherein any heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen [[[[]]] provided the ring is not thereby quaternised [[]]] by methyl, ethyl, acetyl or propionyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidino, morpholino or piperazino ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from fluoro, chloro, bromo, hydroxy, methyl, ethyl and

propylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from methyl, ethyl, acetyl and propionyl [ ] provided the ring is not thereby quaternised[ ]],

and wherein any alkyl or alkanoyl group present as a substituent on the ring formed by R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached is optionally substituted by 1 or 2 substituents independently selected from fluoro, chloro, bromo and hydroxy and/or optionally a substituent selected from methyl, ethyl, methoxy and ethoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents R<sup>1</sup> are both halogeno and attached to the 2- and 3-positions of the ring A, then R<sup>6</sup> is selected from methoxy, ethoxy, propoxy, isopropoxy, substituted-methyl, substituted-ethyl, substituted-propyl, substituted-isopropyl, and substituted-isobutyl, [ ] wherein the substituted groups are substituted by 1 or 2 substituents independently selected from methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido, propionamido, and oxo, or a methoxycarbonyl group together with a hydroxy group, and or an ethoxycarbonyl group together with a hydroxy group[ ]], ~~methoxy, ethoxy, propoxy, isopropoxy,~~

a carbon linked heterocyclyl group selected from azetidiny, oxazepanyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, tetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, tetrahydropyrimidinyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholinyl;

a heteroaryl group selected from pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl;

a (3-7)heterocyclyl(1-6C)alkyl group [ ] wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety [ ] selected from azetidylmethyl, oxazepanylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, tetrahydro-1,4-thiazinylmethyl, piperidinylmethyl, homopiperidinylmethyl, piperazinylmethyl, homopiperazinylmethyl, dihydropyridinylmethyl, tetrahydropyridinylmethyl, dihydropyrimidinylmethyl, tetrahydropyrimidinylmethyl, tetrahydrofuranyl, tetrahydrothienylmethyl, tetrahydropyranylmethyl, tetrahydrothiopyranylmethyl, thiomorpholinylmethyl, 2-(azetidyl)ethyl, 2-(oxazepanyl)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(tetrahydro-1,4-thiazinyl)ethyl, 2-(piperidinyl)ethyl, 2-(homopiperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(homopiperazinyl)ethyl, 2-(dihydropyridinyl)ethyl, 2-(tetrahydropyridinyl)ethyl, 2-(dihydropyrimidinyl)ethyl, 2-(tetrahydropyrimidinyl)ethyl, 2-(tetrahydrofuranyl)ethyl, 2-(tetrahydrothienyl)ethyl, 2-(tetrahydropyranyl)ethyl, 2-(tetrahydrothiopyranyl)ethyl, 2-(thiomorpholinyl)ethyl, a heteroaryl(1-6C)alkyl group selected from pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, thiadiazolylmethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl, 2-(isothiazolyl)ethyl and 2-(thiadiazolyl)ethyl,

and wherein any heteroaryl or heterocyclyl group within  $R^6$  is optionally substituted ~~[[()]]~~ on any available carbon atoms ~~[[()]]~~ by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido, propionamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy and ethoxy,

and wherein any heteroaryl or heterocyclyl group within  $R^6$  is optionally substituted on any available ring nitrogen ~~[[()]]~~ provided the ring is not thereby quaternised ~~[[()]]~~ by methyl, ethyl, acetyl or propionyl;

or  $R^5$  and  $R^6$  together with the nitrogen atom to which they are attached form an azetidin-1-yl ring substituted carbamoyl or (1-3C)alkylenedioxy.

4. (Currently Amended) A quinazoline derivative according to ~~any one of claim~~ ~~[[s]]~~ 1 ~~to 3~~, wherein  $R^5$  is hydrogen, methyl or ethyl and  $R^6$  is selected from hydrogen, methyl, ethyl, propyl, isopropyl, isobutyl, vinyl, isoprop-2-enyl, allyl, but-2-enyl ethynyl, 2-prop-2-ynyl, but-3-ynyl, methoxy, ethoxy, cyclopropyl, cyclopentyl, cyclohexyl, azetidiny, pyrrolinyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrahydropyridinyl, thiomorpholinyl, 1,2,3,6-tetrahydropyridin-1-yl, pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclopentylethyl, 2-cyclohexylethyl, azetidylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, piperidinylmethyl, piperazinylmethyl, tetrahydropyridinylmethyl, thiomorpholinylmethyl, pyrazolylmethyl, thienylmethyl, oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl,

pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, 2-(azetidyl)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(piperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(tetrahydropyridinyl)ethyl, 2-(thiomorpholinyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl and 2-(isothiazolyl)ethyl,

and wherein any alkyl, cycloalkyl, heteroaryl or heterocyclyl group within  $R^5$  or  $R^6$  is optionally substituted  $[[()]]$  on any available carbon atoms $[[()]]$  by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy, and ethoxy,

and wherein any heterocyclyl group within  $R^6$  is optionally substituted on any available ring nitrogen  $[[()]]$  provided the ring is not thereby quaternised $[[()]]$  by methyl, ethyl, acetyl or propionyl, or  $R^5$  and  $R^6$  together with the nitrogen atom to which they are attached form a azetidin-1-yl, pyrrolin-1-yl, pyrrolidin-1-yl, piperidino, morpholino or piperazino ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from fluoro, chloro, hydroxy, methyl, ethyl and propylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from methyl, ethyl, acetyl and propionyl  $[[()]]$  provided the ring is not thereby quaternised $[[()]]$ , and wherein any alkyl or alkanoyl group present as a substituent on the ring formed by  $R^5$  and  $R^6$  together with the nitrogen atom to which they are attached is optionally substituted by 1 or 2 substituents independently selected

from fluoro, chloro and hydroxy and/or optionally a substituent selected from methyl, ethyl methoxy and ethoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents R<sup>1</sup> are both halogeno and attached to the 2- and 3-positions of the ring A, then R<sup>6</sup> is selected from methoxy, ethoxy, substituted-methyl, substituted-ethyl substituted-propyl, substituted-isopropyl, substituted-isobutyl, (wherein the substituted groups are substituted by 1 or 2 substituents independently selected from methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido and oxo or a methoxycarbonyl group together with a hydroxy group), ~~methoxy, ethoxy~~,

a carbon linked heterocyclyl group selected from azetidinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyridinyl, tetrahydropyranyl, thiomorpholinyl,

a heteroaryl group selected from pyrazolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidyl, furanyl, pyrazolyl, thiazolyl, isothiazolyl,

a (3-7)heterocyclyl(1-6C)alkyl group ~~[[[]]]~~ wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety~~[[[]]]~~ selected from azetidylmethyl, pyrrolinylmethyl, pyrrolidinylmethyl, morpholinylmethyl, piperidinylmethyl, piperazinylmethyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinylmethyl, thiomorpholinylmethyl, 2-(azetidiny)ethyl, 2-(pyrrolinyl)ethyl, 2-(pyrrolidinyl)ethyl, 2-(morpholinyl)ethyl, 2-(piperidinyl)ethyl, 2-(piperazinyl)ethyl, 2-(tetrahydrofuranyl)ethyl, 2-(tetrahydropyranyl)methyl, 2-(tetrahydropyridinyl)ethyl, 2-(thiomorpholinyl)ethyl, a heteroaryl(1-6C)alkyl group selected from pyrazolylmethyl, thienylmethyl,

oxazolylmethyl, isoxazolylmethyl, imidazolylmethyl, pyridinylmethyl, pyridazinylmethyl, pyrazinylmethyl, pyrimidylmethyl, furanylmethyl, pyrazolylmethyl, thiazolylmethyl, isothiazolylmethyl, 2-(pyrazolyl)ethyl, 2-(thienyl)ethyl, 2-(oxazolyl)ethyl, 2-(isoxazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(pyridinyl)ethyl, 2-(pyridazinyl)ethyl, 2-(pyrazinyl)ethyl, 2-(pyrimidyl)ethyl, 2-(furanyl)ethyl, 2-(pyrazolyl)ethyl, 2-(thiazolyl)ethyl and 2-(isothiazolyl)ethyl,

and wherein any heteroaryl or heterocyclyl group within  $R^6$  is optionally substituted ~~[[()]]~~ on any available carbon atoms ~~[[()]]~~ by 1 or 2 substituents independently selected from fluoro, chloro, bromo, hydroxymethyl, 2-hydroxyethyl, methoxycarbonyl, ethoxycarbonyl, carbamoyl, acetamido and hydroxy and/or optionally a substituent selected from oxo, cyano, methoxy and ethoxy,

and wherein any heteroaryl or heterocyclyl group within  $R^6$  is optionally substituted on any available ring nitrogen ~~[[()]]~~ provided the ring is not thereby quaternised ~~[[()]]~~ by methyl, ethyl, acetyl or propionyl;

or  $R^5$  and  $R^6$  together with the nitrogen atom to which they are attached form an azetidin-1-yl ring substituted by a carbamoyl group.

5. (Currently Amended) A quinazoline derivative according to ~~any one of claim~~ ~~[[s]]~~ 1 to 4, wherein  $R^5$  is hydrogen or methyl and  $R^6$  is selected from hydrogen, methyl, ethyl, propyl, isopropyl, vinyl, isoprop-2-enyl, allyl, but-2-enyl ethynyl, 2-propynyl, but-3-ynyl, methoxy, cyclopropyl, cyclopentyl, 1-(hydroxymethyl)cyclopentyl, cyclohexyl, 4-hydroxycyclohexyl, cyclopropylmethyl, cyclopentylmethyl, methoxymethyl, 2-(methoxy)ethyl, 2-(ethoxy)ethyl, carbamoylmethyl, 2-(acetyl)ethyl, cyanomethyl, 2-

(cyano)ethyl, 2,3-dihydroxypropyl, 2-(hydroxyl)-1,1-dimethylethyl, 2,2,2-trifluoroethyl, 1-(ethoxycarbonyl)-2-hydroxyethyl, 2-acetamidoethyl, tetrahydrofuran-2-ylmethyl, imidazol-2-ylmethyl, 1-methylpyrazol-5-yl, 1-methylpyrazol-5-yl, 3-methylpyrazol-5-yl, imidazol-1-ylmethyl, 2-(imidazol-1-yl)ethyl, furan-2-ylmethyl, 2-(furan-2-yl)ethyl, 5-methylisoxazol-3-ylmethyl, thien-3yl, morpholino, piperidin-4-yl, 1-methylpiperidin-4-yl, tetrahydro-2H-pyran-4-yl and 3-oxotetrahydrofuran-4-yl,

or R<sup>5</sup> and R<sup>2</sup> together with the nitrogen atom to which they are attached form a 3-hydroxyazetidin-1-yl, 2-carbamoylazetidin-1-yl, pyrrolin-1-yl, pyrrolidin-1-yl, 3-hydroxy, pyrrolidin-1-yl, piperidino, morpholino or piperazino group;

provided that when the pyrrolidinyl group is linked to the 6-position of the quinazoline ring, m is 2 and substituents R<sup>1</sup> are both halogeno and attached to the 2- and 3-positions of the ring A, then R<sup>6</sup> is selected from methoxy, carbamoylmethyl, 2-(hydroxy)-1-(methoxycarbonyl)ethyl, 1-(ethoxycarbonyl)-2-hydroxyethyl, 2-(acetamido)ethyl, piperidin-4-yl, 1-methylpiperidin-4-yl, tetrahydropyran-4-yl, 4-hydroxytetrahydrofuran-3-yl, 3-oxotetrahydrofuran-4-yl, 1-methylpyrazol-5-yl, thien-3yl, 3-methylpyrazol-5-yl, tetrahydrofuran-2-ylmethyl, tetrahydropyran-4-ylmethyl, furan-2-ylmethyl, 2-(furan-2-yl)ethyl, imidazol-1-ylmethyl, imidazol-2-ylmethyl, imidazol-2-ylmethyl, 2-(imidazol-1-yl)ethyl, 2-(imidazol-4-yl)ethyl and 5-methylisoxazol-3-ylmethyl or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form an azetidiny substituted in the 2 position by a carbamoyl group.

6. (Currently Amended) A quinazoline derivative according to claim 1 ~~or claim 2~~, wherein R<sup>5</sup> is hydrogen or (1-6C)alkyl and R<sup>6</sup> is selected from hydrogen, (1-6C)alkyl, (2-



6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (3-7)cycloalkyl, (1-6C)alkylsulfonyl, heterocyclyl, heteroaryl, (3-7)cycloalkyl(1-3C)alkyl, (3-7)heterocyclyl(1-3C)alkyl and heteroaryl(1-3C)alkyl, and wherein any (1-3C)alkyl, (1-6C)alkyl, (3-7)cycloalkyl, heteroaryl or heterocyclyl group within R<sup>5</sup> or R<sup>6</sup> is optionally substituted [[[ ]]] on any available carbon atoms[[[ ]]] by 1, 2 or 3 substituents independently selected from halogeno, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen [[[ ]]]provided the ring is not thereby quaternised[[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl, or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from halogeno, hydroxy, (1-4C)alkyl and (1-3C)alkylenedioxy, and optionally substituted on any available ring nitrogen by a substituent selected from (1-4C)alkyl and (2-4C)alkanoyl [[[ ]]]provided the ring is not thereby quaternised[[[ ]]].

and wherein any (1-4C)alkyl or (2-4C)alkanoyl group present as a substituent on the ring formed by R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached is optionally substituted by 1, 2 or 3 substituents independently selected from halogeno and hydroxy and/or optionally a substituent selected from (1-4C)alkyl and (1-4C)alkoxy;

provided that when the pyrrolidinyloxy group is linked to the 6-position of the quinazoline ring, m is 2 and substituents R<sup>1</sup> are both halogeno and attached to the 2- and 3-positions of the ring A, then R<sup>6</sup> is selected from (3-7)heterocyclyl [[[ ]]]wherein

heterocyclyl is carbon linked[[ ]], heteroaryl, (3-7)heterocyclyl(1-6C)alkyl [[ ]]wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety[[ ]]] and heteroaryl(1-6C)alkyl, and wherein any heteroaryl or (3-7)heterocyclyl group within R<sup>6</sup> is optionally substituted [[ ]]on any available carbon atoms[[ ]]] by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy, and wherein any heteroaryl or heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen [[ ]]provided the ring is not thereby quaternised[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl.

7. (Currently Amended) A quinazoline derivative according to claim 1~~anyone of the preceding claims~~, wherein m is 0, 1, 2 or 3 and R<sup>1</sup> is independently selected from halogeno, cyano, nitro, hydroxy, trifluoromethyl, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, ureido, N-(1-6C)alkylureido, N,N-di-[(1-6C)alkyl]ureido, --NR<sup>a</sup>R<sup>b</sup>, --SO<sub>2</sub>NR<sup>a</sup>R<sup>b</sup> and a group of the formula --CONR<sup>a</sup>R<sup>b</sup> [[ ]]wherein R<sup>a</sup> and R<sup>b</sup> are as hereinabove defined[[ ]]];

or, when two R<sup>1</sup> groups are attached to adjacent carbon atoms, they may, together with the carbon atoms to which they are attached, form a pyrrole ring, wherein the pyrrole ring is optionally substituted by 1 or 2 substituents independently selected from (1-6C)alkyl, halogeno, cyano, nitro, hydroxy, amino, carbamoyl, sulfamoyl and trifluoromethyl;

or, when two R<sup>1</sup> groups are attached to adjacent carbon atoms, they may, together form a (1-3C)alkylenedioxy group.

8. (Currently Amended) A quinazoline derivative according to claim 7, wherein m is 0, 1 or 2 and R<sup>1</sup> is independently selected from fluoro, chloro, cyano, trifluoromethyl, methyl, methoxy, methylthio, isobutylthio, sulfamoyl, and a group of the formula --CONR<sup>a</sup>R<sup>b</sup> [[[wherein R<sup>a</sup> is hydrogen or methyl and R<sup>b</sup> selected from hydrogen, methyl, ethyl, isobutyl, furanyl, cyclopentyl and cyclohexyl,

wherein any alkyl, (3-7)cycloalkyl, heteroaryl in R<sup>a</sup> and R<sup>b</sup> are optionally substituted by 1 or 2 substituents selected from hydroxy and methoxy;

or R<sup>a</sup> and R<sup>b</sup> together with the nitrogen atom to which they are attached form a 1,2,3,6-tetrahydropyridin-1-yl, pyrrolidin-1-yl, piperidino, piperazin-1-yl or morpholino ring, which is optionally substituted by 1 or 2 substituents on an available ring carbon atom, independently selected from hydroxyl and optionally substituted on any available ring nitrogen by a substituent selected from methyl and acetyl [[[provided the ring is not thereby quaternised[[[),

or, when two R<sup>1</sup> groups are attached to adjacent carbon atoms, they may, together with the carbon atoms to which they are attached, form a pyrrole ring, wherein the pyrrole ring is optionally substituted by 1 or 2 substituents independently selected from hydroxy; or, when two R<sup>1</sup> groups are attached to adjacent carbon atoms, they may, together form a (1-3C)alkylenedioxy group.

9. (Currently Amended) A quinazoline derivative according to claim 7 ~~or claim 8~~,

wherein m is 2 and R<sup>a</sup> is positioned in the 2- and 3-positions of ring A and R<sup>1</sup> is independently selected from fluoro and chloro.

10. (Currently Amended) A quinazoline derivative according to claim 9~~any one of the preceding claims~~, wherein ring A is phenyl or pyrid-3-yl.

11. (Currently Amended) A quinazoline derivative according to claim 10~~any one of the preceding claims~~, wherein ring A is phenyl.

12. (Currently Amended) A quinazoline derivative according to claim 1~~any one of the preceding claims~~, wherein R<sup>2</sup> is selected from hydrogen, (1-6C)alkyl and a group of the formula R<sup>7</sup>O-, wherein R<sup>7</sup> is (1-6C)alkyl optionally substituted by 1 or 2 substituents independently selected from hydroxy and a group of the formula R<sup>8</sup>O- ~~[[()]]~~ wherein R<sup>8</sup> is (1-3C)alkyl~~[[()]]~~.

13. (Currently Amended) A quinazoline derivative according to claim 12~~any one of the preceding claims~~, wherein R<sup>2</sup> is selected from hydrogen, methyl, ethyl and a group of the formula R<sup>7</sup>O-, wherein R<sup>7</sup> is methyl or ethyl.

14. (Currently Amended) A quinazoline derivative according to claim 13~~any one of the preceding claims~~, wherein R<sup>2</sup> is methoxy.

15. (Currently Amended) A quinazoline derivative according to any one of claims 4-

~~to claim~~ 13, wherein  $R^2$  is hydrogen.

16. (Currently Amended) A quinazoline derivative according to claim 1~~any one of the preceding claims~~, wherein  $R^2$  is in the 6-position and the substituted-pyrrolidinyloxy group is in the 7-position of the quinazoline ring.

17. (Currently Amended) A quinazoline derivative according to claim 1~~any one of claims 1 to 15~~, wherein  $R^2$  is in the 7-position and the substituted-pyrrolidinyloxy group is in the 6-position of the quinazoline ring.

18. (Currently Amended) A quinazoline derivative according to claim 1~~any one of the preceding claims~~, wherein  $R^3$  is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-3C)alkyl (2-6C)alkanoyl;

and wherein any (1-6C)alkyl or (2-6C)alkanoyl group within  $R^3$  is optionally substituted by 1 or 2 substituents independently selected from halogeno, hydroxy and (1-6C)alkyl and/or optionally a substituent selected from cyano, nitro, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy and  $NR^cR^d$ , wherein  $R^c$  is hydrogen or (1-4C)alkyl and  $R^d$  is hydrogen or (1-4C)alkyl.

19. (Currently Amended) A quinazoline derivative according to claim 18~~any one of the preceding claims~~, wherein  $R^3$  is methyl.

20. (Currently Amended) A quinazoline derivative according to claim 1~~any one of the~~


~~preceding claims~~, wherein n is 0, 1 or 2 and R<sup>4</sup> is independently selected from methyl, ethyl, methoxy, ethoxy, hydroxyl and oxo.

21. (Currently Amended) A quinazoline derivative according to claim 20~~anyone of the preceding claims~~, wherein n is 0.

22. (Currently Amended) A quinazoline derivative according to claim 1~~anyone of the preceding claims~~, wherein the --CONR<sup>5</sup>R<sup>6</sup> group is in the 2-position of the pyrrolidine ring.

23. (Currently Amended) A quinazoline derivative according to claim 1~~anyone of the preceding claims~~, wherein the substituted-quinazolinyl group is in the 3-position of the pyrrolidine ring.

24. (Currently Amended) A quinazoline derivative according to claim 1~~any one of the preceding claims~~ having a structural sub-formula A2:



wherein:

m is 2 and R<sup>1</sup> is 2-fluoro and 3-chloro;

R<sup>2</sup> is methoxy;

R<sup>3</sup> is methyl;

n is 0; and

R<sup>5</sup> is hydrogen or (1-6C)alkyl and R<sup>6</sup> is selected from ~~substituted (1-6C)alkyl~~  
~~(wherein substituted (1-6C)alkyl is (1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-7)heterocyclyl~~  
~~(wherein the heterocyclyl is carbon linked), heteroaryl, (3-7)heterocyclyl(1-6C)alkyl~~  
~~wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety, heteroaryl(1-~~  
~~6C)alkyl, (1-6C)alkyl substituted by 1, 2 or 3 substituents independently selected from~~  
~~(1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino, and oxo, or and a (1-~~  
~~6C)alkoxycarbonyl together with a hydroxy group), (1-6C)alkoxy, (1-6C)alkylsulfonyl, (3-~~  
~~7)heterocyclyl (wherein the heterocyclyl is carbon linked), heteroaryl, (3-~~  
~~7)heterocyclyl(1-6C)alkyl (wherein the heterocyclyl is carbon linked to the (1-6C)alkyl~~  
~~moiety) and heteroaryl(1-6C)alkyl,~~

and wherein any heteroaryl or (3-7)heterocyclyl group within R<sup>6</sup> is optionally substituted ~~[[[]]]~~ on any available carbon atoms ~~[[[]]]~~ by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy, and wherein any heteroaryl or heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen ~~[[[]]]~~ provided the ring is not thereby quaternised ~~[[[]]]~~ by (1-4C)alkyl or (2-4C)alkanoyl,

or R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered ring which contains one or two nitrogen atoms as the only heteroatoms present in the ring and which is optionally and which is substituted on an available ring carbon atom by 1 or 2 substituents independently selected from carbamoyl and (1-3C)alkylenedioxy.

25. (Currently Amended) A quinazoline derivative according to claim 24, wherein R<sup>6</sup> is selected from (3-7)heterocyclyl [[[ ]] wherein the heterocyclyl is carbon linked[[ ]]], heteroaryl, (3-7)heterocyclyl(1-6C)alkyl [[[ ]] wherein the heterocyclyl is carbon linked to the (1-6C)alkyl moiety[[ ]]], and heteroaryl(1-6C)alkyl,

and wherein any heteroaryl or (3-7)heterocyclyl group within R<sup>6</sup> is optionally substituted [[[ ]] on any available carbon atoms[[ ]]] by 1, 2 or 3 substituents independently selected from halogeno, (1-6C)alkyl, hydroxy(1-6C)alkyl, (1-6C)alkoxycarbonyl, carbamoyl, (2-6C)alkanoylamino and hydroxy and/or optionally a substituent selected from oxo, cyano, nitro and (1-4C)alkoxy,

and wherein any heteroaryl or heterocyclyl group within R<sup>6</sup> is optionally substituted on any available ring nitrogen [[[ ]] provided the ring is not thereby quaternised[[ ]]] by (1-4C)alkyl or (2-4C)alkanoyl.

26. (Original) A quinazoline derivative selected from one or more of the following:  
(4S)-4-{{4-[(3-chloro-2-fluorophenyl)amino]quinazolin-7-yl}oxy)-N,N,1-tri- methyl-L-prolinamide;  
(4S)-4-{{4-[(3-chloro-2-fluorophenyl)amino]quinazolin-7-yl}oxy)-1-methyl-L-prolinamide;



(4S)-4-({4-[(4-cyano-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-4-cyanophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-[(3-chloro-4-(trifluoromethyl)phenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(5-chloropyridin-3-yl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2-fluoro-4-methylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2-fluoro-4-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2,4-difluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(2,5-difluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(5-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(4-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(5-chloro-2-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-4-methoxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-[(2-(aminosulfonyl)-5-chlorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({7-methoxy-4-[(2,3,4-trifluorophenyl)amino]quinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-[(2-fluoro-5-(trifluoromethyl)phenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-[(4-[(2-fluoro-3-(trifluoromethyl)phenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-methoxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-methylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-4-hydroxyphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-cyanophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(1H-indol-5-ylamino)-7-methoxyquinazolin-6-yl]oxy}-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-1H-indol-5-yl)amino]-7-methoxyquinazolin-6-yl]oxy}-N,N,1-trimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-cyclopropyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-(cyclopropylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-(2-methoxyethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-cyclopentyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-cyclopentylmethyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-(2-methoxyethyl)-N,1-dimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-methoxy-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-N-cyclohexyl-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]oxy}-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-D-prolinamide; and

(4S)-4-({4-[(3-chloro-4-fluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)-N,N,1-trimethyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(3-furylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-furylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-[(5-methylisoxazol-3-yl)methyl]-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(1H-imidazol-1-yl)ethyl]-1-methyl-D-prolinamide;

(2S)-1-[(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolyl]azetidine-2-carboxamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2R)-2,3-dihydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(1-methyl-1H-pyrazol-5-yl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-3-thienyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(3-methyl-1H-pyrazol-5-yl)-D-prolinamide;

methyl(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolyl-L-serinate;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolylglycinamide;

(4S)-N-[2-(acetlamino)ethyl]-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[1-(hydroxymethyl)cyclopentyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(1H-imidazol-4-yl)ethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxy-1-methylethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(2,2,2-trifluoroethyl)-D-prolinamide;

(4S)-N-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-D-prolinamide (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-ethoxyethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(4-hydroxycyclohexyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(2-methylprop-2-en-1-yl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-1-(hydroxymethyl)propyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2S)-2,3-dihydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(1H-imidazol-2-ylmethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(2-furyl)ethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1S)-2-hydroxy-1-methylethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1R)-2-hydroxy-1-methylethyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2R)-2-hydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(2S)-2-hydroxypropyl]-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-[(2R)-tetrahydrofuran-2-ylmethyl]-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-[(2S)-tetrahydrofuran-2-ylmethyl]-D-prolinamide N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[[[(3S,5R)-1-methyl-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl]oxy]quinazolin-4-amine; N-(3-chloro-2-fluorophenyl)-7-methoxy-6-[[[(3S,5R)-1-methyl-S-[(4methylpiperazin-1-yl)carbonyl]pyrrolidin-3-yl]oxy]quinazolin-4-amine 6-[[[(3S,5R)-5-(azetidin-1-ylcarbonyl)-1-methylpyrrolidin-3-yl]oxy]-N-(3-chloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine; (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-N,1-dimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-1-methyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-[(2S)-2-pyrrolidin-1-ylpropyl]-D-prolinamide; (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[(1R)-2-hydroxy-1-methylethyl]-N,1-dimethyl-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(1-methylpiperidin-4-yl)-D-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-D-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-prop-2-yn-1-yl-L-prolinamide;

1-[[[(2S,4R)-4-[[4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-methyl-2-pyrrolidinyl]carbonyl]-3-pyrroline;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-cyanoethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyanomethyl)-N,1-dimethyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopropyl-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopentyl-1-methyl-L-prolinamide;

N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(((3R,5S)-1-methyl-5-[(methylpiperazin-1-yl)carbonyl]pyrrolidin-3-yl}oxy)quinazolin-4-amine;

(3S)-1-[(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-L-prolyl]pyrrolidin-3-ol (4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyclopropylmethyl)-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-N,1-dimethyl-L-prolinamide;



(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-L-prolinamide;

N-(3-chloro-2-fluorophenyl)-7-methoxy-6-(((3R,5S)-1-methyl-5-(pyrrolidin-1-ylcarbonyl)pyrrolidin-3-yl}oxy)quinazolin-4-amine;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-hydroxyethyl)-N,1-dimethyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-[2-(dimethylamino)ethyl]-1-methyl-L-prolinamide;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(1-methylpiperidin-4-yl)-L-prolinamide;

6-(((3R,5S)-5-[(4-acetylpiperazin-1-yl)carbonyl]-1-methylpyrrolidin-3-yl}oxy)-N-(3-chloro-2-fluorophenyl)-7-methoxyquinazolin-4-amine;

1-[(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-L-propyl]piperidin-4-ol;

(4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-N,1-dimethyl-L-prolinamide; (4R)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopropyl-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-1-methyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-N,1-dimethyl-L-prolinamide;

(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-1-methyl-N-(tetrahydro-2H-pyran-4-yl)-L-prolinamide;  
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(2-methoxyethyl)-N,1-dimethyl-L-prolinamide;  
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N,1-dimethyl-N-(1-methylpiperidin-4-yl)-L-prolinamide;  
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclopentyl-1-methyl-L-prolinamide;  
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-methoxy-1-methyl-L-prolinamide;  
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-(cyclopropylmethyl)-1-methyl-L-prolinamide;  
(4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-cyclohexyl-1-methyl-L-prolinamide;  
and pharmaceutically-acceptable salts thereof.

27. (Original) (4S)-4-({4-[(3-chloro-2-fluorophenyl)amino]quinazolin-7-yl}oxy)-1-methyl-L-prolinamide trifluoroacetic acid salt.

28. (Currently Amended) A pharmaceutical composition which comprises a quinazoline derivative of the Formula I, or a pharmaceutically-acceptable salt or ~~prodrug~~ form thereof, as defined in claim 1 ~~any one of claims 1 to 25~~ in association with a pharmaceutically-acceptable diluent or carrier.


29. (Currently Amended) A quinazoline derivative of the Formula I as defined in claim 1 ~~any one of claims 1 to 25~~, or a pharmaceutically acceptable salt or ~~prodrug form~~ thereof, for use as a medicament.

30. (Cancelled)

31. (Currently Amended) A method for producing an anti-proliferative effect in a warm-blooded animal in need of such treatment, which comprises administering to, said animal a quinazoline derivative of the Formula I, or a pharmaceutically acceptable salt or ~~prodrug form~~ thereof, as defined in claim 1 ~~any one of claims 1 to 25~~.


32. (Currently Amended) A process for the preparation of a quinazoline derivative of the Formula I as defined in claim 1 which is selected from one of the following:

**Process (a)** reacting a compound of the Formula II:



wherein  $R^1$ ,  $R^2$ , A, m and n have any of the meanings defined in claim 1, except that any functional group is protected if necessary,

with a compound of the Formula III in the presence of a suitable base:



wherein  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and  $p$  have any of the meanings defined in claim 1, except that any functional group is protected if necessary and  $Lg$  is a displaceable group, and

whereafter any protecting group that is present is removed;

**Process (b)** modifying a substituent in, or introducing a substituent into, another quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1, except that any functional group is protected if necessary, and

whereafter any protecting group that is present is removed;


**Process (c)** the removal of a protecting group from a quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof, as claimed in claim 1;

**Process (d)** reacting a compound of the Formula II as defined in reference to process (a) above with a compound of the Formula III as defined in reference to process (a) above, except  $Lg$  is  $OH$ , under Mitsunobu conditions, and

whereafter any protecting group that is present is removed by conventional means;

**Process (e)** For the preparation of those compounds of the Formula I defined in claim 1 wherein  $R^4$  is a hydroxy group, by the cleavage of a quinazoline derivative of the Formula I wherein  $R^4$  is a (1-4C)alkoxy group;

**Process (f)** For the preparation of those compounds of the Formula I defined in claim 1 wherein  $R^4$  is (1-4C)alkoxy, by the reaction of a compound of the Formula IV:




with a compound of the formula (1-4C)alkyl-Lg in the presence of a base, wherein Lg is a displaceable group, and

whereafter any protecting group that is present is removed by conventional means;

**Process (g)** For the preparation of those compounds of the Formula I defined in claim 1 wherein  $R^1$ ,  $R^2$ ,  $R^4$  or  $R^6$  contain a (1-6C)alkoxy or substituted (1-6C)alkoxy group or a (1-6C)alkylamino or substituted (1-6C)alkylamino group, said process comprising the alkylation of a quinazoline derivative of the Formula I wherein  $R^1$ ,  $R^2$ ,  $R^4$  or  $R^6$  contain a hydroxy group or a primary or secondary amino group as appropriate;

**Process (h)** reacting a compound of the formula (V) or reactive derivative thereof with a compound of the formula  $\text{HNR}^5\text{R}^6$  or a suitable salt thereof in the presence of a base and in an inert solvent;

**Process (i)** reacting a compound of the formula VI: wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  n and p, have any of the meanings defined in claim 1, except that any functional group is protected if necessary, and Lg is a displaceable group as defined in reference to Process (a) above,  
with an aniline of the formula VII in the presence of a suitable acid:



wherein  $R^1$  and m have any of the meanings defined defined in claim 1, except that any functional group is protected if necessary,

**Process (j)** Forming the group  $-\text{CON}(R^5)R^6$  by reacting to the corresponding carboxy compound, wherein any functional groups are protected if necessary, with a primary or secondary amine or a heterocyclic group containing an NH group; and

whereafter any protecting group that is present is removed by conventional means.

33. (New) The method according to claim 31, wherein said anti-proliferative effect treats a cancer.

34. (New) The method according to claim 31, wherein said cancer is chosen from leukemia, multiple myeloma, lymphoma, bile duct, bone, bladder, brain/CNS, breast,

colorectal, endometrial, gastric, head, neck, hepatic, lung, neuronal, oesophageal,  
ovarian, pancreatic, prostate, renal, skin, testicular, thyroid, uterine, and vulval cancers.